Manufacturing Expansion

QuVa Pharma has commenced manufacturing in newly completed Suites 4 and 5 at its facility in Bloomsbury, New Jersey, substantially increasing capacity. As the company experiences significant growth, these two new compounding suites will allow an increase in total output of compounded sterile preparations by more than 50%. Customer demand for compounded sterile medications sourced from FDA approved product has become a dominant driver of the company’s future business; as such, added capacity will allow QuVa to satisfy increasing customer demand for sterile sourced product well into 2019.

QuVa Pharma, Inc